FLT4 anticorps
-
- Antigène Voir toutes FLT4 Anticorps
- FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))
-
Reactivité
- Souris
-
Hôte
- Rat
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp FLT4 est non-conjugé
-
Application
- Flow Cytometry (FACS)
- Purification
- The antibody was purified by affinity chromatography.
- Clone
- AFL4
- Isotype
- IgG2a kappa
- Top Product
- Discover our top product FLT4 Anticorps primaire
-
-
- Indications d'application
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Concentration
- 0.5 mg/mL
- Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- 4 °C
- Stockage commentaire
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
- Antigène
- FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))
- Autre désignation
- VEGFR-3 (FLT4 Produits)
- Synonymes
- anticorps FLT41, anticorps LMPH1A, anticorps PCL, anticorps VEGFR3, anticorps AI323512, anticorps Chy, anticorps Flt-4, anticorps VEGFR-3, anticorps Vegfr3, anticorps cb1059, anticorps fms related tyrosine kinase 4, anticorps FMS-like tyrosine kinase 4, anticorps fms-related tyrosine kinase 4, anticorps FLT4, anticorps Flt4, anticorps flt4
- Sujet
- VEGFR-3, also known as FLT4, is a member of the Tyr protein kinase family. The extracellular portion of VEGFR-3 contains 7 immunoglobulin (Ig)-like domains and the cytoplasmic portion contains a protein kinase domain. FLT4 regulates angiogenesis and lymphangiogenesis, its ligands are VEGF-C and D and its binding is mediated by the 2nd and 3rd Ig-like domains of FLT4. During fetal development VEGFR-3 is expressed on endothelial cells, however, in the adult mice, the vascular endothelial cells lose VEGFR-3 expression, but the lymphatic endothelium expresses it constitutively. In addition, VEGFR-3 expression can be induced in tumors with active angiogenesis.
- Pathways
- Signalisation RTK, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling
-